Consent to Receive MRI Gadolinium – Renal Patients

Recently the FDA (Food and Drug Administration) has identified, through various global studies, that the use of the Intravenous (IV) MRI Contrast Gadolinium has the potential of causing Nephrogenic Systemic Fibrosis (NSF) in stage 3,4,5 Renal Failure / Dialysis patients.

NSF is a *rare* disabling disease affecting 3-5% of Renal Failure patients. It attacks body systems by causing fibrosis (scar tissue / connective tissue fibers) involving the skin (causing scaring and tightening), the joints (causing deformities and arthritis) and influences the functioning of other vital organs with fatal outcomes. Symptoms of this disease, if it is to occur, happen within 2 – 11 weeks after receiving the contrast.

The American College of Radiology (ACR), a committee of Radiologists that set guidelines for radiology practice, has issued the following recommendations:

- Stage 3,4,5 Renal Failure/Dialysis patients are to be dialyzed ***immediately*** (within 2 hours) after receiving the contrast.
- An additional dialysis session should be done within 24 hours of the initial dialysis session.

If you have any questions, you may speak with a radiologist before making the decision to sign this consent.

☐ I would like to speak with a radiologist before making a decision to receive the contrast.

☐ I waive my right to speak with a radiologist.

☐ Based on the information received, **I refuse** the administration of IV contrast.

☐ Based on the above information, **I consent to receive** the IV contrast. All my questions have been fully answered to my satisfaction and I believe I have sufficient information to base my decision on.

Print Patient's Name	Signature of Patient or Designee

MD, RN or Tech Signature	Title	Date/Time